Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease

Rhea-AI Summary

On May 23, 2021, Synlogic, Inc. (SYBX) presented data on its Synthetic Biotic medicines aimed at treating inflammatory bowel disease (IBD) during Digestive Disease Week. The presentation, delivered by Mylene Perreault, showcased an investigational program focusing on a novel IL-22-secreting Synthetic Biotic. Synlogic aims to leverage synthetic biology to innovate treatments for various diseases, with a proprietary pipeline also targeting metabolic disorders like Phenylketonuria. The event was held virtually from May 21-23, 2021.

Positive

• Presentation of novel IL-22-secreting Synthetic Biotic for IBD at a prominent conference.
• Continued development of a proprietary pipeline for metabolic disorders and other diseases.

Negative

• None.

CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of  inflammatory bowel disease (IBD) during Digestive Disease Week (DDW), being held virtually May 21-23, 2021.

The presentation, "A Novel IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease," was delivered by Mylene Perreault, Synlogic's Senior Director and Head of Biology. The presentation recording will be available throughout the duration of the conference.

Learn more about Synlogic's programs and development pipeline by visiting https://www.synlogictx.com/.

About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The company is also building a portfolio of partner-able assets in immunology and oncology.

Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618 and availability of clinical trial data including Phase 2 data of SYNB1618 for the treatment of PKU. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View original content:http://www.prnewswire.com/news-releases/synlogic-presents-data-at-digestive-disease-week-ddw-on-a-novel-approach-for-the-treatment-of-inflammatory-bowel-disease-301297408.html

SOURCE Synlogic, Inc.

FAQ

What was presented by Synlogic at Digestive Disease Week 2021?

Synlogic presented data on a novel IL-22-secreting Synthetic Biotic medicine for treating inflammatory bowel disease.

When did Synlogic present its findings at DDW?

The findings were presented on May 23, 2021.

What is the ticker symbol for Synlogic?

The ticker symbol for Synlogic, Inc. is SYBX.

What is the purpose of Synlogic's Synthetic Biotic medicines?

They are designed to target and treat diseases, including inflammatory bowel disease and metabolic disorders.

Who delivered the presentation for Synlogic?

The presentation was delivered by Mylene Perreault, the Senior Director and Head of Biology.